HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

Results suggest new hope for patients with refractory chronic lymphocytic leukemia Data to support BLA submission

BARCELONA, SPAIN, June 12 ---ILEXTM Oncology, Inc. (NASDAQ: ILXO) and LeukoSite, Inc. (NASDAQ: LKST) today announced final results from an international, multi-center, pivotal Phase II clinical trial of CAMPATHR for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who are refractory to fludarabine. Results of the trial were presented this weekend at the 4th Congress of the European Haematology Association (EHA) by Michael J. Keating, MB, BS, of the M.D. Anderson Cancer Center, one of the trial's principal investigators and an internationally recognized expert in CLL. The companies plan to submit a Biologics License Application (BLA) based largely on these results later this year.

"The results of this trial are encouraging," said Dr. Keating, Associate Head for Clinical Research and Professor of Medicine and internist for the Department of Leukemia at M.D. Anderson Cancer Center. "The data suggest that CAMPATH may provide an important new treatment option for fludarabine-refractory patients, a group for whom the prognosis has, to date, been extremely poor. While the treatment of patients with leukemia has relied on chemotherapeutic agents, the use of monoclonal antibodies is an innovative approach to circumventing the disease's mechanisms for resistance."

The non-comparative trial, involved 93 previously treated patients who had received prior alkylating agents and failed fludarabine therapy (median of three prior treatment regimens). For these patients, the median life expectancy is usually six to nine months.

In the trial, patients participating at the 20 clinical sites in the United States and Europe received 30 mg of CAMPATH on an outpatient basis, as an intravenous infusion, three times a week, for four to 12 weeks. The dose was gradually escalated over the first week to 30 mg, in or
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... ... February 20, 2017 , ... Best Doctors® and ... health benefit for companies that want to help members of their workforce battling ... have access to Watson’s suite of oncology offerings for insights on cancer treatment ...
(Date:2/20/2017)... ... 20, 2017 , ... Johns Hopkins All Children's Hospital celebrated a major milestone ... on Friday marked the halfway point of construction and lifting of the final beam ... serve as a center for innovation aimed at finding new discoveries and treatments for ...
(Date:2/20/2017)... ... February 20, 2017 , ... Florida Hospital Pepin Heart ... ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up life-threatening blood clots by ... Family Foundation. , “We greatly appreciate this gift from Constellation Brands. We are ...
(Date:2/19/2017)... ... February 19, 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals ... easily reveal any logo with a glitch reveal in just a few clicks of a ... and animation of each preset. Use these presets to add a uniquely animated logo to ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Free Webinar**, March 1, 2017 — 1:30 p.m. – 2:30 p.m. ET, ... Pay dividends in enhanced and predictable product performance? Streamline processes resulting in ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)...  National Decision Support Company (NDSC) announces its ... Imaging platform within the full range of MEDITECH ... foundation for MEDITECH sites, through a directly supported ... Support Mechanism through the MEDITECH EHR. ... the integration of NDSC,s mechanism, which enables provider ...
(Date:2/20/2017)...   Orion Health ™ announced today ... platform to the Amazon Web Services, Inc. (AWS) ... patient records globally. "We are impressed by ... built on modern, scalable technology," said Steve Halliwell ... AWS Cloud gives healthcare companies a powerful tool to ...
(Date:2/20/2017)... , Feb. 20, 2017  Today from HIMSS17, ... image management suite, announced the launch of  Ambra ... medical imaging. Built around modern, RESTful web-services, this is ... imaging. With these new APIs, IT departments ... and imaging data into other applications such as population ...
Breaking Medicine Technology:
Cached News: